首页 | 本学科首页   官方微博 | 高级检索  
     


Pharmacokinetics,safety and efficacy of a recombinant factor IX product,trenonacog alfa in previously treated haemophilia B patients
Authors:P. W. Collins  D. V. K. Quon  M. Makris  P. Chowdary  C. L. Kempton  S. J. Apte  M. V. Ramanan  C. R. M. Hay  B. Drobic  Y. Hua  T. J. Babinchak  E. D. Gomperts
Affiliation:1. Arthur Bloom Haemophilia Centre, School of Medicine Cardiff University, Cardiff, UK;2. Hemophilia Treatment Center, Orthopaedic Hospital, Los Angeles, CA, USA;3. Department of Haematology, Royal Hallamshire Hospital, Sheffield, UK;4. Katharine Dormandy Haemophilia Care and Thrombosis Unit, Royal Free Hospital NHS Trust, London, UK;5. Department of Hematology and Medical Oncology, Emory University, Atlanta, GA, USA;6. Sahyadri Specialty Hospital, Pune, India;7. Jehangir Clinical Development Centre, Jehangir Hospital, Pune, India;8. Manchester Haemophilia Comprehensive Care Centre, Manchester, UK;9. Clinical Research, Emergent BioSolutions Canada Inc., Winnipeg, MB, Canada;10. Clinical Development and Medical Affairs, Emergent BioSolutions Inc., Berwyn, IL, USA;11. Consultant for Emergent BioSolutions Inc., Montrose, CO, USA
Abstract:
Keywords:efficacy  haemophilia B  IB1001  pharmacokinetics  recombinant factor IX  safety
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号